Skip to main content

Table 1 Ongoing Selected Immunotherapy Trials in Bladder Cancer

From: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Completed
Drug/Agent Study Stage of Disease
Atezolizumab (MPDL3280A) Anti-PD-L1
Cohort 1 NCT02951767, Cohort 2: NCT02108652
Phase II Locally advanced or metastatic – progressed after platinum-based treatment (Rosenberg et al. Lancet 2016; Balar et al. Lancet 2016 [63, 74])
Pembrolizumab
NCT02256436
Phase III vs. standard of care chemotherapy Locally advanced or metastatic – progressed after platinum-based treatment
Ongoing
Drug/Agent Study Stage of Disease
Durvalumab with or without tremelimumab
NCT02516241
Phase II vs. standard of care chemotherapy Stage IV transitional cell carcinoma of the urothelium
Atezolizumab
NCT02662309
Phase II preoperative MPDL3280A Transitional cell carcinoma of the bladder
Atezolizumab combination with cisplatin and gemcitabine
NCT02989584
Pilot safety, single-arm phase II study Metastatic bladder cancer
Atezolizumab
NCT02450331
Randomized phase III atezolizumab as adjuvant therapy vs. observation PD-L1 positive, high risk muscle invasive bladder cancer
Nivolumab
NCT02632409
Randomized phase III nivolumab as adjuvant therapy vs. placebo High risk muscle-invasive bladder cancer
Maintenance avelumab
NCT02603432
Phase III vs. best supportive care alone Locally advanced or metastatic bladder cancer that did not progress after completion of first-line platinum containing chemotherapy
Pembrolizumab
NCT02335424
Phase II Non-cisplatin eligible patients
MEDI-4736 (anti-PD-L1) +/− tremelimumab (anti-CTLA-4) NCT02516241 Phase III, three arms: MEDI-4736 +/− tremelimumab vs. standard of care chemotherapy Unresectable stage IV bladder cancer